Jazz Pharmaceuticals (JAZZ) Receivables (2010 - 2026)

Jazz Pharmaceuticals' Receivables history runs 17 years deep, the most recent figure standing at $836.3 million for Q1 2026.

• In Q1 2026, Receivables rose 28.07% year-over-year to $836.3 million; the TTM figure through Mar 2026 stood at $836.3 million (up 28.07% YoY), while the FY2025 annual figure was $830.7 million, up 15.9% from the prior year.
• Receivables was $836.3 million for Q1 2026 at Jazz Pharmaceuticals, up from $830.7 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $836.3 million in Q1 2026 to a low of $572.4 million in Q1 2022.
• Historically, Receivables has averaged $684.2 million across 5 years, with a median of $698.0 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Receivables soared 38.27% in 2022, then decreased 7.65% in 2025.
• A 5-year view of Receivables shows it stood at $651.5 million in 2022, then climbed by 8.33% to $705.8 million in 2023, then advanced by 1.55% to $716.8 million in 2024, then climbed by 15.9% to $830.7 million in 2025, then advanced by 0.67% to $836.3 million in 2026.
• The last three Receivables figures came in at $836.3 million (Q1 2026), $830.7 million (Q4 2025), and $764.4 million (Q3 2025), per Business Quant data.